AU2014283319B2 - Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders - Google Patents

Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders Download PDF

Info

Publication number
AU2014283319B2
AU2014283319B2 AU2014283319A AU2014283319A AU2014283319B2 AU 2014283319 B2 AU2014283319 B2 AU 2014283319B2 AU 2014283319 A AU2014283319 A AU 2014283319A AU 2014283319 A AU2014283319 A AU 2014283319A AU 2014283319 B2 AU2014283319 B2 AU 2014283319B2
Authority
AU
Australia
Prior art keywords
compound
formula
disease
hyperkinetic movement
huntington
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014283319A
Other languages
English (en)
Other versions
AU2014283319A1 (en
Inventor
Nuria Gavalda Batalla
Raul Insa Boronat
Nuria Reig Bolano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Som Innovation Biotech SA
Original Assignee
Som Innovation Biotech SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48672545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2014283319(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Som Innovation Biotech SA filed Critical Som Innovation Biotech SA
Publication of AU2014283319A1 publication Critical patent/AU2014283319A1/en
Application granted granted Critical
Publication of AU2014283319B2 publication Critical patent/AU2014283319B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2014283319A 2013-06-19 2014-06-18 Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders Active AU2014283319B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13382230.4 2013-06-19
EP13382230 2013-06-19
PCT/EP2014/062786 WO2014202646A1 (en) 2013-06-19 2014-06-18 Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders

Publications (2)

Publication Number Publication Date
AU2014283319A1 AU2014283319A1 (en) 2016-02-11
AU2014283319B2 true AU2014283319B2 (en) 2019-07-25

Family

ID=48672545

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014283319A Active AU2014283319B2 (en) 2013-06-19 2014-06-18 Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders

Country Status (19)

Country Link
US (2) US9789072B2 (enExample)
EP (1) EP3010543B1 (enExample)
JP (1) JP6476174B2 (enExample)
KR (1) KR102254542B1 (enExample)
CN (1) CN105658238B (enExample)
AU (1) AU2014283319B2 (enExample)
BR (1) BR112015031835B1 (enExample)
CA (1) CA2915811C (enExample)
CL (1) CL2015003679A1 (enExample)
DK (1) DK3010543T3 (enExample)
ES (1) ES3053333T3 (enExample)
IL (1) IL243192B (enExample)
MX (1) MX366353B (enExample)
PL (1) PL3010543T3 (enExample)
PT (1) PT3010543T (enExample)
RU (1) RU2685502C2 (enExample)
SG (1) SG11201510451RA (enExample)
WO (1) WO2014202646A1 (enExample)
ZA (1) ZA201600312B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41557A (fr) * 2015-02-18 2017-12-26 Auspex Pharmaceuticals Inc Inhibiteurs diméthoxyphényles du transporteur vésiculaire des monoamines 2
CA3076000A1 (en) * 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
US20200230127A1 (en) 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790165A (fr) * 1971-12-14 1973-02-15 Parke Davis & Co Nouveaux aminoalcanols et procede pour les preparer
ES2569483T3 (es) 2007-06-21 2016-05-11 Amgen Inc. Métodos para sintetizar cinacalcet y sales del mismo
CL2008002793A1 (es) * 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
US8197858B2 (en) 2009-02-06 2012-06-12 Mark John Zamoyski Bone microenvironment modulated seizure treatments
EP2705842A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
RS53227B (sr) * 2011-03-01 2014-08-29 Pharnext Terapija neuroloških poremećaja kombinacijom baklofena i akamprosata
UA115968C2 (uk) 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lofdahl, CG et al (1984) Pharmacotherapy 4: 205-210 *

Also Published As

Publication number Publication date
MX366353B (es) 2019-07-05
EP3010543A1 (en) 2016-04-27
NZ715951A (en) 2021-03-26
PT3010543T (pt) 2025-11-28
US9789072B2 (en) 2017-10-17
PL3010543T3 (pl) 2026-01-19
CL2015003679A1 (es) 2016-09-02
CA2915811C (en) 2021-08-31
SG11201510451RA (en) 2016-01-28
EP3010543B1 (en) 2025-11-05
US20180042869A1 (en) 2018-02-15
RU2685502C2 (ru) 2019-04-19
CN105658238B (zh) 2019-07-12
JP6476174B2 (ja) 2019-02-27
BR112015031835B1 (pt) 2022-12-13
KR102254542B1 (ko) 2021-05-24
RU2016101152A (ru) 2017-07-24
BR112015031835A2 (pt) 2017-07-25
JP2016522235A (ja) 2016-07-28
MX2015018040A (es) 2016-08-03
IL243192A0 (en) 2016-02-29
WO2014202646A1 (en) 2014-12-24
IL243192B (en) 2019-12-31
KR20160055121A (ko) 2016-05-17
AU2014283319A1 (en) 2016-02-11
BR112015031835A8 (pt) 2019-12-31
CA2915811A1 (en) 2014-12-24
ZA201600312B (en) 2022-12-21
US20160158167A1 (en) 2016-06-09
HK1223014A1 (en) 2017-07-21
DK3010543T3 (da) 2025-12-01
CN105658238A (zh) 2016-06-08
ES3053333T3 (en) 2026-01-21

Similar Documents

Publication Publication Date Title
TWI494293B (zh) 用於治療認知障礙之α-胺基醯胺衍生物
EP1829544A1 (en) Pharmaceutically active morpholinol
HU226138B1 (en) R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof
CA2864012C (en) Therapeutic approaches for treating parkinson's disease
MX2015003608A (es) Combinacion de laquinimod y pridopidina para tratar trastornos neurodegenerativos.
AU2020324856B2 (en) Small molecule drugs and related methods for treatment of diseases related to TDP-43, alpha-synuclein, Huntingtin's protein and tau protein oligomer formation
JP2015180673A (ja) トランスノルセルトラリン及びセロトニン受容体１ａ作動剤／拮抗剤を含む組成物及びその使用
EP2455075A1 (en) Combinations of Eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, & Cognitive Disorders
CA2915811C (en) Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders
JP2024149602A (ja) 境界性パーソナリティ障害の処置方法
CN104173332A (zh) 银杏内酯类化合物的新用途
JP5198293B2 (ja) アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤
HK1223014B (en) Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders
US7098206B2 (en) Pharmaceutically active morpholinol
NZ715951B2 (en) Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders
CA3102826A1 (en) Disease modifying methods for treating neurodegenerative diseases using nootropic agents
JP2022138903A (ja) 抗うつ又は抗不安薬

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)